Dr. Orest Lastow, Iconovo AB - Qepler Summits And Conferences

Dr. Orest Lastow

Chief Technology Officer & Founder
Iconovo AB
Malmo, Sweden
Iconovo AB

Dr. Orest Lastow is the founder and CTO of Iconovo AB. He is also the former CEO of Iconovo and is the inventor of Iconovo’s four inhalation device platforms. He is also the founder and previous CEO of Medicon Valley Inhalation Consortium, MVIC AB. Orest was with AstraZeneca for over 15 years and is the principal inventor of AstraZeneca’s new dry powder inhalation platform. Orest is the inventor behind over 40 patents and patent applications.

Orest received a M.Sc. in Engineering Physics and a Licentiate of Engineering degree in Aerosol Science from Lund University. He has also a Ph.D. in electrohydrodynamic atomisation from Brunel University. His expertise is device development, electrostatics, Computational Fluid Dynamics (CFD), aerosol science and inhalation technology. He is the author behind a textbook on EHD atomisation, several journal publications and book contributions. He is frequently invited to speak at conferences and teaches aerosol drug delivery at Lund University and Copenhagen University. Orest is a co-author of the Aerosol drug delivery device design verification standard (ISO 20072).

Related Sessions:

Inhaled Drug Delivery
Summit 2019

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 23 May 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 23 May 2019
CASE STUDY: Development of a generic triple combination product – hurdles and opportunities.
  • Why triple combinations to treat asthma and COPD? What are the clinical benefits?
  • API combinations on the market or in the clinical pipeline
  • Formulation challenges with triple combination
  • Special device requirements and availability
  • Hurdles and opportunities for generic companies
View Details

2nd Annual Inhaled
Drug Delivery Summit 2021

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 05 Aug 2021
  • Virtual,
  • Pharma
Day 2: Friday, 06 August 2021
CASE STUDY: ICOpre - Development of a generic DPI platform for a global market

Generic versions of marketed dry powder inhaler (DPI) drug products represent an attractive market opportunity. In the coming years, GSK’s Ellipta platform is the largest opportunity with several drug substance patents expiring. However, development of generic DPI drug products is a complicated process with many challenges. Complex drug-device interactions represent a major hurdle to achieve therapeutic equivalence. The very intricate patent landscape in combination with the requirement of similar user-handling and flow resistance limits the design options. The need for cost-efficient development and low manufacturing costs adds additional complexity. There is a great need to replace injections with safe and low cost inhaled drug delivery. Iconovo’s unit-dose inhaler ICOone is currently used in two ongoing projects on inhaled oxytocin and inhaled covid-19 vaccine.

  • Overview of market and patent situation.
  • Regulatory requirements on generic inhalation products.
  • Initial choice – copy original or develop new technology.
  • Concurrent development of device and formulation.
  • ICOone – inhalation instead of injection.
View Details